Tag: PD-1 inhibitors

An analysis of nearly half a million clinical trials and real-world data from over 91,000 patients reveals that immune-related side ...

A new review synthesizes clinical trial evidence showing that combining radiotherapy with immune checkpoint inhibitors can dramatically boost response rates ...

A multicenter study finds that skeletal muscle measured on routine staging CT scans predicts treatment tolerance, surgical complications and survival ...

A pharmacovigilance analysis of US and Japanese adverse event databases finds that PD-1 and PD-L1 checkpoint inhibitors show a robust, ...

A revised meta-analysis of six phase III trials shows first-line PD-1 inhibitor plus chemotherapy reduces the risk of death by ...

A new multi-disciplinary expert consensus provides a detailed framework for diagnosing and treating the skin toxicities caused by immune checkpoint ...

A phase 2a trial found that surufatinib combined with PD-1/PD-L1 inhibitors as first-line maintenance therapy yielded a median progression-free survival ...

A translational modelling study finds that PD-1 receptor occupancy does not predict immune activation during pembrolizumab therapy, challenging current dosing ...

A real-world study of 87 patients suggests that combining Trop-2 antibody-drug conjugates with PD-1 inhibitors and anti-angiogenic therapy substantially improves ...

In the evolving landscape of cancer treatment, a pivotal study uncovers promising results involving the combination of Sitravatinib and Tislelizumab ...